A Phase 1/2 Study of CS7017, an Oral PPARĪ³ Agonist, in Combination With Paclitaxel
Status:
Terminated
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The Phase I/II study will be conducted as an open label, multiple center study of CS-7017, an
experimental drug and paclitaxel chemotherapy in subjects with advanced anaplastic thyroid
cancer. Biopsies will be obtained from patients with accessible tumor at baseline, two-weeks
after the first CS-7017 dosage (prior to the start of combination therapy) and at the end of
the first study cycle (week 3 of combination therapy), in order to evaluate the effects of
the study drug alone and in combination with the chemotherapy agent on the tumor. Treatment
will continue until disease progression or the development of intolerable toxicities.